Phase 2Completed
A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Weekly CT-388 Administered for 48 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
- Sponsor
- Carmot Therapeutics, Inc. (Industry)
- Enrolment
- 469 enrolled
- Conditions
- Obesity; Overweight
- Interventions
- Placebo; Enicepatide
- Ages
- adults, older adults
- Registry
- NCT06525935
From the registry
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants with obesity or who are overweight with at least one weight-related comorbidity.
Primary outcomes
- Percent Change in Body Weight from Baseline to Week 48